[Skip to Content]
[Skip to Content Landing]
Viewpoint
October 16, 2013

Data and Safety Monitoring BoardsAcademic Credit Where Credit Is Due?

Author Affiliations
  • 1Canadian VIGOUR Centre, Division of Cardiology, Department of Medicine, University of Alberta, Edmonton, Canada
  • 2Duke Translational Medicine Institute, Duke University, Durham, North Carolina
  • 3Division of Cardiology, Duke University School of Medicine, Durham, North Carolina
JAMA. 2013;310(15):1563-1564. doi:10.1001/jama.2013.280383

The growth of clinical trials has emerged as an indispensable foundation and major source of advances in medicine and human health. Their proliferation, size, complexity, and cost have engendered several recent consensus conferences; the reports arising reflect broad concern about the future sustainability of the current model of clinical trials.1,2 These initiatives have also variously called for greater efficiency, increasing end point validity and relevance, more adaptable and flexible designs, and better return on the investment of diverse stakeholders.

First Page Preview View Large
First page PDF preview
First page PDF preview
×